BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 31462588)

  • 1. Progression of Hypopituitarism and Hypothyroidism after Treatment with Pembrolizumab in a Patient with Adrenal Metastasis from Non-small-cell Lung Cancer.
    Yamagata S; Kageyama K; Takayasu S; Asari Y; Makita K; Terui K; Daimon M
    Intern Med; 2019 Dec; 58(24):3557-3562. PubMed ID: 31462588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyponatremia in a Patient With Cancer.
    Uppal NN; Wanchoo R; Barnett R; Sinha A; Jhaveri KD
    Am J Kidney Dis; 2020 Jan; 75(1):A15-A18. PubMed ID: 31864502
    [No Abstract]   [Full Text] [Related]  

  • 3. Simultaneous Presentation of Secondary Adrenal Insufficiency and Primary Hypothyroidism due to Pembrolizumab: A Case Report.
    Khatri S; Alom M; Kashfi S; Atallah J; Goswami G
    J Investig Med High Impact Case Rep; 2023; 11():23247096231194401. PubMed ID: 37642143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pembrolizumab-induced hypothyroidism caused reversible increased serum creatinine levels: a case report.
    Matsuoka N; Tsuji K; Ichihara E; Hara T; Fukushima K; Toma K; Kitamura S; Inagaki K; Sugiyama H; Wada J
    BMC Nephrol; 2020 Mar; 21(1):113. PubMed ID: 32234009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitor-Associated Central Adrenal Insufficiency.
    Mishra T; He G; Sreeram K; Rauf M; Subahi A; Hazem M
    Am J Ther; 2019; 26(5):e626-e627. PubMed ID: 30277909
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
    Imai H; Wasamoto S; Yamaguchi O; Suzuki K; Sugiyama T; Uchino J; Minemura H; Osaki T; Ishii H; Umeda Y; Mori K; Kotake M; Kagamu H; Morozumi N; Taniguchi H; Kasai T; Minato K; Kaira K
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):457-466. PubMed ID: 31853661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.
    Gandhi L; Rodríguez-Abreu D; Gadgeel S; Esteban E; Felip E; De Angelis F; Domine M; Clingan P; Hochmair MJ; Powell SF; Cheng SY; Bischoff HG; Peled N; Grossi F; Jennens RR; Reck M; Hui R; Garon EB; Boyer M; Rubio-Viqueira B; Novello S; Kurata T; Gray JE; Vida J; Wei Z; Yang J; Raftopoulos H; Pietanza MC; Garassino MC;
    N Engl J Med; 2018 May; 378(22):2078-2092. PubMed ID: 29658856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
    Katsume Y; Isawa T; Toi Y; Fukuda R; Kondo Y; Sugawara S; Ootomo T
    Intern Med; 2018 Nov; 57(21):3157-3162. PubMed ID: 29877257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab-induced obstructive bronchiolitis in a patient with stage IV non-small-cell lung cancer.
    Blanchard A; Bouchard N
    Curr Oncol; 2019 Aug; 26(4):e571-e573. PubMed ID: 31548826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases.
    Fujita K; Uchida N; Kanai O; Okamura M; Nakatani K; Mio T
    Cancer Chemother Pharmacol; 2018 Jun; 81(6):1105-1109. PubMed ID: 29675747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful Treatment of Non-small-cell Lung Cancer with Atezolizumab Following Tubulointerstitial Nephritis Due to Pembrolizumab.
    Taki T; Oda N; Fujioka Y; Mitani R; Tokura T; Takata I; Oshiro Y; Takigawa N
    Intern Med; 2020 Jul; 59(13):1639-1642. PubMed ID: 32269191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: reinitiating pembrolizumab treatment after small bowel perforation.
    Beck TN; Kudinov AE; Dulaimi E; Boumber Y
    BMC Cancer; 2019 Apr; 19(1):379. PubMed ID: 31018834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
    Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
    Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer.
    Huang M; Pietanza MC; Samkari A; Pellissier J; Burke T; Chandwani S; Kong F; Pickard AS
    Pharmacoeconomics; 2019 Jan; 37(1):105-116. PubMed ID: 30515719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal Effects after Pembrolizumab Treatment for Non-small Cell Lung Carcinoma.
    Oki R; Hirakawa Y; Kimura H; Honda K; Hinata M; Abe H; Domoto Y; Tanaka G; Nagase T; Nangaku M
    Intern Med; 2020 Apr; 59(7):977-981. PubMed ID: 31813918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Tubulointerstitial Nephritis: A Case Report on Rare Adverse Effect of Pembrolizumab.
    Basnet S; Dhital R; Tharu B
    Medicina (Kaunas); 2019 May; 55(5):. PubMed ID: 31117208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
    Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
    J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer.
    Kurokawa K; Mitsuishi Y; Shimada N; Ito N; Ogiwara M; Miura K; Asao T; Ko R; Shukuya T; Shibayama R; Goto H; Takahashi K
    Thorac Cancer; 2023 Feb; 14(5):442-449. PubMed ID: 36523162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compromise or not? A case report of successful treatment of pembrolizumab-induced hepatitis in a patient with non-small cell lung cancer with low-dose methylprednisolone and bicyclol.
    Liu Y; Zhang J; Yin Z; Zhu X; Xue L; Cao B
    Thorac Cancer; 2020 Jul; 11(7):2023-2030. PubMed ID: 32379397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.